Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/26032
Title: | Global Issues of Radiopharmaceutical Access and Availability: A Nuclear Medicine Global Initiative Project. | Austin Authors: | Cutler, Cathy S;Bailey, Elizabeth;Kumar, Vijay;Schwarz, Sally W;Bom, Hee-Seung;Hatazawa, Jun;Paez, Diana;Orellana, Pilar;Louw, Lizette;Mut, Fernando;Kato, Hiroki;Chiti, Arturo;Frangos, Savvas;Fahey, Frederic;Dillehay, Gary;Oh, Seung J;Lee, Dong S;Lee, Sze Ting ;Nunez-Miller, Rodolfo;Bandhopadhyaya, Guru;Pradhan, Prasanta K;Scott, Andrew M | Affiliation: | Brookhaven National Laboratory, Upton, New York Department of Molecular Imaging and Therapy, Austin Health; University of Melbourne; Olivia Newton-John Cancer Research Institute, and School of Cancer Medicine, La Trobe University, Melbourne, Australia Department of Nuclear Medicine, Royal North Shore Hospital, Sydney, New South Wales, Australia Department of Biomedical Sciences, Humanitas University, and Nuclear Medicine Unit, Humanitas Research Hospital-IRCCS, Milan, Italy University of Melbourne Excel Diagnostics and Nuclear Oncology Center, Houston, Texas Nuclear Medicine and Diagnostic Imaging Section, International Atomic Energy Agency, Vienna, Austria Department of Nuclear Medicine and PET, Westmead Hospital and Children's Hospital at Westmead, and University of Sydney, New South Wales, Australia Washington University School of Medicine, St Louis, Missouri Department of Nuclear Medicine, Chonnam National University Hwasun Hospital, Jeollanam, Korea Department of Quantum Cancer Therapy, Research Center for Nuclear Physics, Osaka University, Osaka, Japan Nuclear Medicine and Diagnostic Imaging Section, International Atomic Energy Agency, Vienna, Austria Department of Nuclear Medicine, Charlotte Maxeke Johannesburg Academic Hospital and University of Witwatersrand, Johannesburg, South Africa Nuclear Medicine Service, Italian Hospital, Montevideo, Uruguay Department of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine, Osaka, Japan Department of Nuclear Medicine, Bank of Cyprus Oncology Center, Nicosia, Cyprus Department of Radiology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts Department of Radiology, Division of Nuclear Medicine, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul, Korea Department of Nuclear Medicine, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India Department of Nuclear Medicine, Sanjay Gandhi Post Graduate Institute of Nuclear Medicine, Lucknow, India School of Cancer Medicine, La Trobe University, Melbourne, Australia Olivia Newton-John Cancer Research Institute Molecular Imaging and Therapy |
Issue Date: | Mar-2021 | Date: | 2020-07-09 | Publication information: | Journal of Nuclear Medicine 2021; 62(3): 422-430 | Abstract: | The Nuclear Medicine Global Initiative was formed in 2012 by 13 international organizations to promote human health by advancing the field of nuclear medicine and molecular imaging by supporting the practice and application of nuclear medicine. The first project focused on standardization of administered activities in pediatric nuclear medicine and resulted in 2 articles. For its second project the Nuclear Medicine Global Initiative chose to explore issues impacting on access and availability of radiopharmaceuticals around the world. Methods: Information was obtained by survey responses from 35 countries on available radioisotopes, radiopharmaceuticals, and kits for diagnostic and therapeutic use. Issues impacting on access and availability of radiopharmaceuticals in individual countries were also identified. Results: Detailed information on radiopharmaceuticals used in each country, and sources of supply, was evaluated. Responses highlighted problems in access, particularly due to the reliance on a sole provider, regulatory issues, and reimbursement, as well as issues of facilities and workforce, particularly in low- and middle-income countries. Conclusion: Strategies to address access and availability of radiopharmaceuticals are outlined, to enable timely and equitable patient access to nuclear medicine procedures worldwide. In the face of disruptions to global supply chains by the coronavirus disease 2019 outbreak, renewed focus on ensuring a reliable supply of radiopharmaceuticals is a major priority for nuclear medicine practice globally. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/26032 | DOI: | 10.2967/jnumed.120.247197 | Journal: | Journal of Nuclear Medicine | PubMed URL: | 32646881 | Type: | Journal Article | Subjects: | access global issues radiopharmaceuticals |
Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.